Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SENL101 autologous T-cell injection in CD7-positive relapsed or refractory T-lymphoblastic lymphoma/leukemia
CTR20253965Phase 2Active
- Sponsor
- Senlang Bio
- Start
- Jan 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of SENL101 in T-lymphoblastic lymphoma (T-LBL), Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL), sponsored by Senlang Bio. Started Jan 2026; status: active.
02
Drugs
SENL101
03
Conditions
T-lymphoblastic lymphoma (T-LBL)Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL)
Beyond the preview
Go deeper on CTR20253965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253965.